High level of low
density lipoprotein (LDL) cholesterol in blood may turn
life-threatening, as it deposits in the blood vessels, narrowing the
lumen, and leads to coronary heart diseases. This condition is
commonly called atherosclerosis. LDL apheresis is a procedure that
involves withdrawing blood from the patient’s body, removing LDL
cholesterol and pumping the remaining blood back into the patient’s
body. The LDL apheresis procedure is recommended to patients with
familial hypercholesterolemia (FH), a common genetic disorder that
leads to a high level of LDL cholesterol. This procedure is also
performed for patients who are non-responsive to medications for
lowering blood LDL cholesterol levels. The heterozygous type of FH
has prevalence of 1 in 500 across all the countries, while the
homozygous FH is found in 1 in 10 million population.
Request Report
Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=28493
According to the
World Health Organization, in 2008, the prevalence of elevated total
cholesterol was 54% in Europe, 48% in North America, and 29% in
Southeast Asia. It is estimated that one-third of the heart diseases
are caused due to elevated level of cholesterol in the blood.
Lifestyle-induced diseases, pollution, and other metabolic diseases
are further projected to increase the number of patients with
atherosclerosis. Other application areas for LDL apheresis therapy
are under study such as renal diseases, hematology diseases, and
others. This is projected to drive the demand for LDL apheresis
machines and disposables in the near future. Moreover, favorable
reimbursement scenario in developed markets such as North America and
Europe is driving more patients to opt for LDL apheresis therapy.
However, the procedure attracts high capital investment in terms of
device and set up. It also attract expensive consumables and skilled
healthcare professionals to perform the procedure, which in turn
makes the procedure expensive.
The global LDL
apheresis therapy market is segmented on the basis of product,
technology, and end-user. In terms of product, the global LDL
apheresis therapy market can be segmented into devices and
disposables, the disposable segment include columns, filters, tubing,
etc. In terms of technology, the global LDL apheresis therapy market
can be segmented into double filtration plasmapheresis or cascade
filtration, immunoadsorption, heparin-induced LDL precipitation
(HELP), dextran sulphate lipid adsorption, and hemoperfusion. The
hemoperfusion is performed by advanced procedures such as direct
adsorption of lipoproteins (DALI) and whole blood perfusion
(Liposorber D). Dextran sulfate lipid adsorption and HELP are the
most widely employed techniques for LDL apheresis in recent years.
However, technically advanced hemoperfusion systems are found to be
more promising and are anticipated to dominate the market in near
future due to their efficiency and simplicity of use. In terms of
end-user, the global LDL apheresis therapy market can be segmented
into hospitals, ambulatory surgical centers, and blood banks.
Enquiry for
discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=28493
In terms of
geography, the global LDL apheresis therapy market can be segmented
into North America, Europe, Asia Pacific, and Rest of the World.
North America is estimated to hold a prominent share of the global
LDL apheresis therapy market and is anticipated to expand at a high
growth rate due to acceptance of technology, well-established
healthcare industry, and high healthcare expenditure from the public
and private sector. Europe is projected to follow North America in
terms of share of the global LDL apheresis therapy market due to
increasing prevalence of elevated cholesterol in blood and
developments in healthcare infrastructure. Technical advancements in
markets such as Japan and increasing healthcare expenditure in
emerging markets such as India and China are likely to propel the LDL
apheresis therapy market in Asia Pacific in the near future.
Major players
operating in the global LDL apheresis therapy market include Kaneka
Pharma Europe N.V, B. Braun Melsungen AG, Fresenius Medical Care AG &
Co. KGaA, Asahi Kasei Medical Co., Ltd., Medicap GmbH, Kawasumi
Laboratories Inc. Terumo Corporation, and Haemonetics Corporation.
About Us
Transparency Market
Research is a next-generation market intelligence provider, offering
fact-based solutions to business leaders, consultants, and strategy
professionals.
Our reports are
single-point solutions for businesses to grow, evolve, and mature.
Our real-time data collection methods along with ability to track
more than one million high growth niche products are aligned with
your aims. The detailed and proprietary statistical models used by
our analysts offer insights for making right decision in the shortest
span of time. For organizations that require specific but
comprehensive information we offer customized solutions through adhoc
reports. These requests are delivered with the perfect combination of
right sense of fact-oriented problem solving methodologies and
leveraging existing data repositories.
TMR believes that
unison of solutions for clients-specific problems with right
methodology of research is the key to help enterprises reach right
decision.
US Office
Contact
90 State Street,
Suite 700
Albany, NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment